No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
1 out of 7 registries used, show all original rules. |
109 |
4. Check minimum number of eventsNone |
109 |
5. Include endpointsNone |
109 |
6. Filter based on genotype QC (FinnGen only) |
109 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- C
- First used in FinnGen datafreeze
- DF5
Similar endpoints
↥List of similar endpoints to
Epileptic seizures related to drugs
based on the number of shared cases.
Similar with more cases:
- Epilepsy
- Episodal and paroxysmal disorders
- Neurological diseases
- Neurological diseases, wide definition
- Any operation in hilmo
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 693 | 270 | 422 |
| Only index persons | 667 | 264 | 403 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 34.78 | 37.41 | 33.12 |
| Only index persons | 34.73 | 37.19 | 33.12 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 109 | 50 | 59 |
| Unadjusted period prevalence (%) | 0.02 | 0.02 | 0.03 |
| Median age at first event (years) | 39.61 | 42.00 | 37.58 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 105
- Matched controls
- 1051
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
G40.52
ICD-10 Finland
Epileptic seizures related to drugs
+∞
151.4
105
*
R56.8
ICD-10 Finland
Other and unspecified convulsions
78.0
59.4
66
22
N05AH02
ATC
clozapine; systemic
71.4
58.3
66
24
112
Kela drug reimbursment
Severe psychotic and other severe mental disorders
44.2
57.5
79
67
N03AG01
ATC
valproic acid; systemic, rectal
35.4
46.9
64
44
N05AH03
ATC
olanzapine; systemic
24.6
40.5
63
60
F20.00
ICD-10 Finland
Paranoid schizophrenia continuous
41.3
37.6
47
20
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
35.9
36.1
47
23
N05AX08
ATC
risperidone; systemic
20.6
33.6
54
51
N03AX09
ATC
lamotrigine; oral
29.3
32.1
44
25
F29
ICD-10 Finland
Unspecified nonorganic psychosis
21.2
31.9
50
43
N05AH04
ATC
quetiapine; oral
13.3
31.2
70
137
N05BA01
ATC
diazepam; systemic, rectal
16.2
30.1
54
64
F20.9
ICD-10 Finland
Schizophrenia, unspecified
29.9
29.5
40
21
N05BA06
ATC
lorazepam; systemic, sublingual
27.4
28.1
39
22
N05AA02
ATC
levomepromazine; systemic
21.8
27.8
42
31
T36
ICD-10 Finland
Poisoning by systemic antibiotics
20.6
27.7
43
34
F20.30
ICD-10 Finland
Undifferentiated schizophrenia continuous
41.1
27.6
34
12
G40.9
ICD-10 Finland
Epilepsy, unspecified
32.8
26.0
34
15
N05AX12
ATC
aripiprazole; systemic
15.3
24.9
44
47
N04AA02
ATC
biperiden; systemic
41.2
24.4
30
10
AA1AD
NOMESCO Finland
CT of head and brain
9.7
23.0
56
110
N05BA04
ATC
oxazepam; oral
8.8
22.6
62
147
N05CD07
ATC
temazepam; oral
14.1
21.7
39
42
N05AF03
ATC
chlorprothixene; systemic
21.4
20.9
31
20
N05AB03
ATC
perphenazine; systemic, rectal
22.8
20.7
30
18
P72
ICPC
Schizophrenia
21.7
19.8
29
18
X69
ICD-10 Finland
Intentional self-poisoning by and exposure to other and unspecified chemicals and noxious substances
14.2
17.8
31
30
N03AE01
ATC
clonazepam; systemic
14.8
16.5
28
25
N06AB04
ATC
citalopram; systemic
6.6
16.3
51
131
F10.1
ICD-10 Finland
Mental and behavioural disorders due to use of alcohol, Harmful use
14.2
16.2
28
26
C07AA05
ATC
propranolol; systemic
6.4
15.3
48
122
N06AB06
ATC
sertraline; oral
7.7
15.2
39
75
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
10.3
15.1
31
41
N05AD01
ATC
haloperidol; systemic
27.0
14.9
20
9
N06AX11
ATC
mirtazapine; oral
5.5
14.8
59
198
N05CF01
ATC
zopiclone; oral
5.5
14.4
54
168
F10.21
ICD-10 Finland
Alcohol dependence currently abstinent, but staying in restrictive environment
159.8
13.8
14
*
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
9.9
13.6
28
37
F11.22
ICD-10 Finland
Addiction-induced dependence is currently independent but uses substitute intermittent medication
57.7
13.2
15
*
F32.2
ICD-10 Finland
Severe depressive episode without psychotic symptoms
8.3
12.2
28
44
F20.09
ICD-10 Finland
Paranoid schizophrenia UNS
22.2
12.0
17
9
N05AF05
ATC
zuclopenthixol; systemic
34.6
12.0
15
5
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
26.6
12.0
16
7
F20.39
ICD-10 Finland
Undifferentiated schizophrenia UNS
26.6
12.0
16
7
N05AA01
ATC
chlorpromazine; systemic, rectal
26.6
12.0
16
7
P29
ICPC
Psychological sympt/compl other
9.7
11.7
24
31
B18.2
ICD-10 Finland
Chronic viral hepatitis C
20.0
11.7
17
10
F25.9
ICD-10 Finland
Schizoaffective disorder, unspecified
28.8
11.5
15
6
N05BA12
ATC
alprazolam; oral
7.0
11.2
29
54
F41.9
ICD-10 Finland
Anxiety disorder, unspecified
6.2
11.1
32
69
N06AX16
ATC
venlafaxine; oral
5.4
11.0
37
96
C07AB07
ATC
bisoprolol; oral
4.2
10.6
52
197
G40
ICD-10 Finland
Epilepsy
121.7
10.6
11
*
F20
ICD-10 Finland
Schizophrenia
36.7
10.6
13
*
2989X
ICD-9 Finland
Other nonorganic psychoses, Unspecified psychosis
+∞
10.6
10
*
ICZ03
NOMESCO Finland
Participation in compiling a psychiatric treatment plan
13.3
10.5
18
16
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
5.8
10.3
31
70
N03AF02
ATC
oxcarbazepine; oral
15.5
10.1
16
12
EBA00
NOMESCO Finland
Extraction of tooth
3.9
9.9
57
243
A06AD11
ATC
lactulose; oral
7.0
9.9
25
45
R42
ICD-10 Finland
Dizziness and giddiness
4.9
9.7
35
97
N05BE01
ATC
buspirone; oral
12.4
9.7
17
16
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
5.6
9.7
30
70
F20.3
ICD-10 Finland
Undifferentiated schizophrenia
33.5
9.6
12
*
N07BB01
ATC
disulfiram; oral
8.5
9.6
21
30
AA400
NOMESCO Finland
Electroconvulsive therapy
24.4
9.6
13
6
J18.9
ICD-10 Finland
Pneumonia, unspecified
4.6
9.3
36
107
F10.24
ICD-10 Finland
Alcohol depence active use
40.5
9.2
11
*
N06AB03
ATC
fluoxetine; oral
5.4
9.2
29
69
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
5.5
9.1
28
65
K59.09
ICD-10 Finland
Constipation, unspecified
11.6
8.9
16
16
K08.3
ICD-10 Finland
Retained dental root
7.4
8.9
21
34
R25.1
ICD-10 Finland
Tremor, unspecified
18.3
8.8
13
8
F11.25
ICD-10 Finland
Relationship caused by opiates continuously used
30.4
8.7
11
*
IAA01
NOMESCO Finland
Assessment of need for psychiatric treatment
12.3
8.6
15
14
R41.8
ICD-10 Finland
Other and unspecified symptoms and signs involving cognitive functions and awareness
9.4
8.5
17
21
IEY05
NOMESCO Finland
Dedicated profession-specific psychiatric intervention, individual
9.4
8.5
17
21
F10.29
ICD-10 Finland
Addiction caused by alcohol UNS
13.2
8.4
14
12
F20.04
ICD-10 Finland
Paranoid schizophrenia with partial recurrence
19.1
8.3
12
7
183
Kela drug reimbursment
Lamotrigin and topiramate
36.5
8.2
10
*
N05AN01
ATC
lithium; oral
10.7
8.1
15
16
188
Kela drug reimbursment
Psychosis requiring demanding treatment
12.2
8.1
14
13
N05AE03
ATC
sertindole; oral
48.8
7.8
9
*
IEV99
NOMESCO Finland
Other psychiatric network intervention
48.8
7.8
9
*
ICB01
NOMESCO Finland
Psychiatric treatment plan, standard
11.3
7.8
14
14
IGY01
NOMESCO Finland
Accelerated psychiatric treatment contact
11.3
7.8
14
14
SFA10
NOMESCO Finland
Fillning on one surface of tooth
3.4
7.8
76
457
SPAT1240
SPAT
Therapeutic discussion
4.4
7.7
30
88
K08.1
ICD-10 Finland
Loss of teeth due to accident, extraction or local periodontal disease
6.8
7.7
19
33
GD1AA
NOMESCO Finland
Thorax X-ray examination
3.3
7.6
53
250
F60.30
ICD-10 Finland
Emotionally unstable personality disorder, impulsive
12.2
7.5
13
12
EBA05
NOMESCO Finland
Complicated extraction of tooth
3.8
7.5
35
121
P99
ICPC
Psychological disorders other
8.4
7.5
16
22
A49.9
ICD-10 Finland
Bacterial infection, unspecified
6.1
7.4
20
39
F10.20
ICD-10 Finland
Alcohol dependence currently independent
17.3
7.4
11
7
L02.4
ICD-10 Finland
Cutaneous abscess, furuncle and carbuncle of limb
9.9
7.3
14
16
N05CF02
ATC
zolpidem; oral
3.9
7.3
33
111
N05AC02
ATC
thioridazine; oral
13.4
7.3
12
10
G72.8
ICD-10 Finland
Other specified myopathies
21.9
7.3
10
5
K02.1
ICD-10 Finland
Caries of dentine
3.5
7.3
82
533
A28
ICPC
Limited function/disability NOS
5.6
7.2
21
45
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.6
7.2
18
32
N06AA12
ATC
doxepin; systemic
7.7
7.1
16
24
F19.1
ICD-10 Finland
Mental and behavioural disorders due to multiple drug use and use of other psychoactive substances, harmful use
15.2
7.1
11
8
F20.0
ICD-10 Finland
Paranoid schizophrenia
15.2
7.1
11
8
P15
ICPC
Chronic alcohol abuse
10.4
7.0
13
14
J15.9
ICD-10 Finland
Bacterial pneumonia, unspecified
6.4
7.0
18
33
N05AL01
ATC
sulpiride; systemic
18.2
6.9
10
6
SFA30
NOMESCO Finland
Filling on tree or more surfaces of tooth
3.0
6.8
56
289
F13.29
ICD-10 Finland
Addiction caused by sedative and hypnotic UNS
24.4
6.8
9
*
IFA99
NOMESCO Finland
Other psychiatric pharmacotherapy service
24.4
6.8
9
*
SPAT1243
SPAT
Psychiatric/psychological examination
9.7
6.8
13
15
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
11.1
6.7
12
12
SPAT1217
SPAT
Assessment of need for services (elderly/care support)
15.6
6.5
10
7
N88
ICPC
Epilepsy
74.2
6.5
7
*
F11.29
ICD-10 Finland
Addiction caused by opiates UNS
74.2
6.5
7
*
N03AX14
ATC
levetiracetam; systemic
10.2
6.5
12
13
N03AF01
ATC
carbamazepine; oral, rectal
7.9
6.5
14
20
E11.9
ICD-10 Finland
Type 2 diabetes mellitus, without complications
4.2
6.4
25
73
P98
ICPC
Psychosis NOS/other
19.5
6.4
9
5
F32.3
ICD-10 Finland
Severe depressive episode with psychotic symptoms
8.6
6.3
13
17
F25.10
ICD-10 Finland
Schizoaffective syndrome, depressive type with only concomitant bipolar and schizophrenic symptoms
28.6
6.3
8
*
RT250
NOMESCO Finland
NA
+∞
6.3
6
*
2959A
ICD-9 Finland
Schizophrenic psychoses, Unspecified schizophrenia[ERILAISTUMATON SKITSOFRENIA,TARKEMMIN MÄÄRITTELEMÄT]
+∞
6.3
6
*
N05BA09
ATC
clobazam; oral
+∞
6.3
6
*
F20.5
ICD-10 Finland
Residual schizophrenia
+∞
6.3
6
*
P19
ICPC
Drug abuse
13.6
6.2
10
8
R41.0
ICD-10 Finland
Disorientation, unspecified
13.6
6.2
10
8
R4160
NOMESCO Finland
Other therapy enhancing rehabilitation
11.0
6.2
11
11
N06AX12
ATC
bupropion; oral
5.0
6.1
19
44
K04.5
ICD-10 Finland
Chronic apical periodontitis
3.2
6.1
36
147
F10.25
ICD-10 Finland
Alcohol dependence continuous use
16.2
6.0
9
6
F10.26
ICD-10 Finland
Alcohol dependence periodic alcoholism
16.2
6.0
9
6
N03AX16
ATC
pregabalin; oral
3.2
6.0
35
140
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
82
300
8.00
23.19
7.0
7.5
1.2
1.2
mmol/l
2.62
74
280
81
336
6.49
18.58
8.0
8.7
1.2
1.2
mmol/l
1.03
70
294
33
65
6.85
17.29
4.3
3.7
2.9
2.4
mmol/l
0.21
28
49
38
90
5.95
16.40
1.7
1.6
1435.9
1275.0
nmol/l
0.31
33
71
72
299
5.15
15.65
4.8
5.1
34.8
37.3
g/l
2.44
66
287
23
35
8.06
15.14
1.5
1.3
—
—
—
0
0
36
87
5.69
15.09
2.1
1.5
—
—
—
0
0
35
84
5.66
14.75
1.9
1.5
—
—
—
0
0
64
257
4.61
14.16
3.7
2.9
43.5
55.3
u/l
3.46
58
242
23
38
7.40
14.04
6.3
14.3
0.8
0.7
%
0.16
23
38
42
124
4.88
13.80
2.1
1.8
—
—
—
0
0
23
39
7.21
13.70
6.3
14.0
2.0
1.9
%
0.10
23
39
61
244
4.41
13.39
2.9
3.5
2.3
2.3
mmol/l
0.65
52
220
61
246
4.36
13.20
2.3
1.7
100.2
93.0
pmol/l
0.80
40
123
18
24
8.79
13.11
6.7
7.0
1.2
1.2
mmol/l
0.09
18
24
15
5
34.36
12.00
1.7
1.6
15.4
18.2
umol/l
—
15
5
21
38
6.61
11.68
6.8
14.5
91.5
93.1
%
0.36
21
38
78
407
4.22
11.10
7.2
6.6
7.8
10.5
umol/l
3.92
73
388
64
314
3.51
9.53
2.5
2.5
65.0
74.8
nmol/l
1.92
58
285
34
111
4.00
9.41
2.2
2.8
2.4
2.4
mmol/l
0.27
26
102
13
9
16.17
8.44
2.2
1.6
—
—
—
0
0
92
630
3.95
6.96
5.7
4.0
14.3
14.6
pmol/l
0.71
86
586
53
268
2.90
6.91
3.9
2.8
—
—
—
0
0
10
14
7.76
6.82
1.3
1.4
—
—
—
0
0
10
14
7.76
6.82
1.3
1.4
—
—
—
0
0
100
773
4.55
6.37
7.3
4.5
1.9
1.8
mu/l
0.27
92
723
26
92
3.40
6.20
16.5
6.5
—
—
—
0
0
51
266
2.72
6.10
5.4
3.1
54.3
23.5
ng/l
0.49
39
156
35
166
2.63
4.89
2.1
1.8
1.0
0.9
mg/l
0.11
28
126
84
599
2.75
4.85
3.9
3.6
10.3
8.3
mm/h
0.51
76
562
17
54
3.55
4.72
1.4
1.7
—
—
—
0
0
14
41
3.77
4.35
2.1
1.5
—
—
—
0
0
29
137
2.52
4.02
2.8
2.1
0.6
0.8
e6/l
0.22
15
72
90
699
2.65
3.78
7.8
2.9
51.0
40.5
u/l
0.93
85
672
39
217
2.24
3.72
3.6
2.5
0.1
0.3
e6/l
0.91
30
162
99
824
3.20
3.30
6.7
3.5
6.3
5.7
mmol/l
2.67
92
768
6
7
8.98
3.30
1.2
1.0
1122.7
1826.1
miu/ml
—
6
7
103
899
3.64
3.22
29.7
11.8
21.9
20.9
mg/l
0.16
95
678
6
8
7.85
3.09
5.2
1.1
—
—
—
0
0
28
148
2.20
2.96
3.1
3.3
656.6
662.5
ng/l
0.01
21
119
7
14
5.26
2.77
1.1
1.1
—
—
—
0
0
7
15
4.91
2.64
1.1
1.1
—
—
—
0
0
23
121
2.14
2.44
3.5
2.2
1.7
3.3
e6/l
—
10
57
24
133
2.03
2.22
4.3
3.1
13.3
119.0
ng/l
1.36
17
86
7
20
3.67
2.09
1.1
1.3
—
—
—
0
0
34
222
1.77
1.91
7.5
3.1
0.0
0.0
estimate
—
5
81
14
66
2.29
1.91
3.5
3.3
—
—
—
0
0
5
12
4.31
1.84
1.8
2.4
—
—
—
0
0
11
218
0.45
1.76
2.2
2.3
—
—
—
0
0
96
849
2.10
1.74
21.7
10.2
97.2
92.9
ml/min/173m2
1.05
74
682
55
420
1.62
1.70
6.0
3.0
0.0
0.0
estimate
—
7
85
6
19
3.28
1.68
1.2
1.1
—
—
—
0
0
7
26
2.80
1.61
1.0
2.4
166.4
177.5
%
—
7
26
7
27
2.70
1.54
1.3
2.3
89.4
96.3
%
—
7
27
5
15
3.44
1.54
1.2
1.1
—
—
—
0
0
6
21
2.96
1.53
1.0
1.7
—
—
—
0
0
55
428
1.58
1.52
6.2
3.0
0.0
0.0
estimate
—
6
79
14
73
2.05
1.52
1.6
2.0
346.7
400.8
nmol/l
0.46
14
66
11
204
0.49
1.45
2.2
2.2
—
—
—
0
0
6
24
2.58
1.32
1.3
1.6
—
—
—
0
0
6
24
2.58
1.32
1.3
1.6
—
—
—
0
0
53
419
1.52
1.31
7.2
4.2
0.0
0.0
estimate
—
7
84
5
18
2.86
1.30
1.6
1.4
—
—
—
0
0
5
19
2.71
1.23
1.0
1.1
—
—
—
0
0
8
38
2.19
1.21
1.4
1.3
—
—
—
0
0
30
214
1.55
1.17
1.3
1.3
2.0
2.0
u/ml
0.01
12
61
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
0
29
0.00
0.99
0.0
1.5
—
—
—
0
0
68
765
0.70
0.94
3.8
3.6
—
—
—
0
0
97
901
1.70
0.92
6.0
3.8
2.7
2.9
mmol/l
1.12
88
851
22
156
1.51
0.88
2.9
3.7
18.5
23.4
%
—
7
58
6
31
1.99
0.86
1.3
1.1
—
—
—
0
0
96
894
1.62
0.84
5.5
3.6
1.2
1.4
mmol/l
5.08
90
843
43
351
1.37
0.82
5.5
4.3
—
—
—
0
0
0
24
0.00
0.80
0.0
1.3
—
—
—
0
0
96
897
1.59
0.79
5.7
3.6
4.5
4.8
mmol/l
1.69
90
846
41
334
1.36
0.78
6.7
2.9
—
—
—
0
0
93
868
1.49
0.71
5.1
3.3
1.6
1.3
mmol/l
2.15
87
813
12
82
1.52
0.57
2.2
2.0
—
—
—
0
0
6
40
1.53
0.52
1.2
1.8
7.4
2.4
mg/l
—
6
27
13
96
1.40
0.44
2.3
2.2
—
—
—
0
0
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
16
0.00
0.41
0.0
1.1
—
4.3
—
0
7
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
16
0.00
0.41
0.0
2.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
0
17
0.00
0.41
0.0
1.9
—
—
—
0
0
5
36
1.41
0.38
3.0
1.4
—
—
—
0
0
11
144
0.74
0.36
1.6
1.3
—
—
—
0
0
20
167
1.24
0.31
3.5
2.6
—
—
—
0
0
5
41
1.23
0.22
1.0
1.7
35.4
42.0
u/l
—
5
34
0
11
0.00
0.21
0.0
1.7
—
13.3
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
0
10
0.00
0.21
0.0
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.5
—
—
—
0
0
0
10
0.00
0.21
0.0
2.0
—
0.1
—
0
10
5
65
0.76
0.17
1.0
1.3
—
—
—
0
0
23
220
1.06
0.04
1.6
1.6
—
—
—
0
0
0
7
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
6
0.00
0.00
0.0
6.0
—
172.5
—
0
6
0
5
0.00
0.00
0.0
1.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
0
7
0.00
0.00
0.0
1.1
—
—
—
0
0
5
54
0.92
0.00
1.4
3.9
2.7
6.9
ug/l
—
5
44
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
7
0.00
0.00
0.0
4.9
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
5
53
0.94
0.00
2.2
1.7
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
7
0.00
0.00
0.0
5.4
—
74.6
—
0
7
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
0
6
0.00
0.00
0.0
4.7
—
—
—
0
0
0
5
0.00
0.00
0.0
3.0
—
—
—
0
0
0
9
0.00
0.00
0.0
1.1
—
—
—
0
0
0
8
0.00
0.00
0.0
1.3
—
—
—
0
0
0
9
0.00
0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
0.00
0.0
3.2
—
—
—
0
0
0
5
0.00
0.00
0.0
2.0
—
—
—
0
0
0
8
0.00
0.00
0.0
1.4
—
—
—
0
0
0
6
0.00
0.00
0.0
2.7
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint EPILEPTIC_SEIZU_RELATED_DRUGS and mortality.
Females
No dataMales
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| EPILEPTIC_SEIZU_RELATED_DRUGS | 5.024 [2.97, 8.51] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.013 |
During the follow-up period (1.1.1998 — 31.12.2019), 62 out of 360 males with EPILEPTIC_SEIZU_RELATED_DRUGS died.
Mortality risk
Mortality risk for people of age
years, who have EPILEPTIC_SEIZU_RELATED_DRUGS.| N-year risk | Females | Males |
|---|---|---|
| 1 | No data | 1.073% |
| 5 | No data | 6.186% |
| 10 | No data | 14.248% |
| 15 | No data | 25.592% |
| 20 | No data | 40.267% |
Relationships between endpoints
↥Index endpoint: EPILEPTIC_SEIZU_RELATED_DRUGS – Epileptic seizures related to drugs
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data